Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study
Yoshimi Muta; Kazuo Kobayashi; Masao Toyoda; Atsuhito Tone; Daisuke Suzuki; Daisuke Tsuriya; Hideo Machimura; Hidetoshi Shimura; Hiroshi Takeda; Hisashi Yokomizo; Kei Takeshita; Keiichi Chin; Keizo Kanasaki; Kouichi Tamura; Masaaki Miyauchi; Masuo Saburi; Miwa Morita; Miwako Yomota; Moritsugu Kimura; Nobuo Hatori; Shinichi Nakajima; Shun Ito; Shunichiro Tsukamoto; Takashi Murata; Takaya Matsushita; Takayuki Furuki; Takuya Hashimoto; Tomoya Umezono; Yuichi Takashi; Daiji Kawanami
Frontiers in Pharmacology, 27 Mar. 2024
Renoprotective effects of combination treatment with sodium-glucose cotransporter inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus according to preceding medication
Kazuo Kobayashi; Masao Toyoda; Atsuhito Tone; Daiji Kawanami; Daisuke Suzuki; Daisuke Tsuriya; Hideo Machimura; Hidetoshi Shimura; Hiroshi Takeda; Hisashi Yokomizo; Kei Takeshita; Keiichi Chin; Keizo Kanasaki; Masaaki Miyauchi; Masuo Saburi; Miwa Morita; Miwako Yomota; Moritsugu Kimura; Nobuo Hatori; Shinichi Nakajima; Shun Ito; Shunichiro Tsukamoto; Takashi Murata; Takaya Matsushita; Takayuki Furuki; Takuya Hashimoto; Tomoya Umezono; Yoshimi Muta; Yuichi Takashi; Kouichi Tamura
Diabetes and Vascular Disease Research, Nov. 2023
Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report.
Yuichi Takashi; Kyoko Toyokawa; Naoki Oda; Yoshimi Muta; Hisashi Yokomizo; Seiji Fukumoto; Daiji Kawanami
Frontiers in endocrinology, 2022
High-mobility group box 2 protein is essential for the early phase of adipogenesis.
Hidetaka Morinaga; Yoshimi Muta; Tomoko Tanaka; Makito Tanabe; Yuriko Hamaguchi; Toshihiko Yanase
Biochemical and biophysical research communications, 11 Jun. 2021
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease.
Daiji Kawanami; Yuichi Takashi; Yoshimi Muta; Naoki Oda; Dai Nagata; Hiroyuki Takahashi; Makito Tanabe
Frontiers in pharmacology, 2021
Selective androgen receptor modulator, S42 has anabolic and anti-catabolic effects on cultured myotubes.
Yoshimi Muta; Tomoko Tanaka; Yuriko Hamaguchi; Nobuya Hamanoue; Ryoko Motonaga; Makito Tanabe; Takashi Nomiyama; Hajime Nawata; Toshihiko Yanase
Biochemistry and biophysics reports, Mar. 2019
